Login to Your Account



Incivek's Sales Expectations Are up After Strong Launch

By Tom Wall


Monday, August 1, 2011
For those to whom much is given, much is expected. So it is with Vertex Pharmaceutical Inc. as several analysts upped their sales estimates for just-launched hepatitis C treatment Incivek (telaprevir) after the company reported second quarter sales of about $75 million – more than doubling previous Street estimates and more than tripling second quarter sales of $21 million for Merck & Co. Inc.'s competing Victrelis (boceprevir).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription